医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PMC Group International Announces Acquisition of Pharma Company in India

2017年11月01日 PM06:00
このエントリーをはてなブックマークに追加


 

MOUNT LAUREL, N.J.

PMC YM-Pharma Private Ltd., a subsidiary of PMC Group International, an independent arm of PMC Group Inc., announced the acquisition of the assets of Yegna Manojavam Drugs and Chemicals Ltd (YMDCL) of Hyderabad, India. The cGMP manufacturing facility of YMDCL is one of the largest fluoroquinolone drug manufacturers in India and prides itself on its zero-discharge effluent management system. With the additional focus designed to serve the needs of Oncology, Neuropsychiatry, Gastro-Intestinal, Pulmonary Hypertension, Anti-Depressant and Anti-Migraine pharmaceuticals, PMC YM-Pharma Private Ltd plans to become a major market player in providing cost effective generic drugs and drug intermediates to the global market.

“This acquisition begins our journey toward building a global pharmaceutical business,” says Dr. Raj Chakrabarti, Vice President and Chief Strategy Officer of PMC Group International.

About PMC

PMC Group is a growth oriented, diversified, global chemicals and plastics company dedicated to innovative solutions to everyday needs in a broad range of end markets including plastics, consumer products, electronics, paint, packaging, personal care, food, automotive and pharmaceuticals. The Company was built on a sustainable model of growth through innovation while promoting social good. PMC operates from a global manufacturing, innovation and marketing platform with facilities in the Americas, Europe and Asia. More information about PMC and its activities around the world can be found at www.pmc-group.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171101005498/en/

CONTACT

PMC Group International
Patti Griggs, 856-533-1870

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda Announces Information Related to its Pending Voluntary and Conditional Public Takeover Bid for Outstanding Shares and American Depositary Shares of TiGenix
  • Prota/MCRI Completes Enrolment of Phase 2b Multicentre Clinical Trial of Probiotic Oral Immunotherapy for the Treatment of Peanut Allergy (PPOIT-003)
  • Dr. Reddy’s Q4 and FY18 Financial Results
  • 武田薬品が米国臨床腫瘍学会(ASCO)と欧州血液学会(EHA)の年次総会でオンコロジーの広範なポートフォリオとパイプラインのデータを発表
  • ResMed赞助的研究显示,采用居家吸氧与居家无创通气相结合治疗COPD具有成本效益